Topics and Expertise: Drug Discovery

Research into SARS-CoV-2 variants and potential therapies pushes forward

Arkin’s appointment to bolster collaborations between academia and industry for drug discovery.

Team efforts at the School and beyond produce two potential treatments for COVID-19.

The chemical fragments could bind to and disable an enzyme that helps the virus replicate.

ChimeraX, virtual reality software developed at the UCSF Resource for Biocomputing, Visualization and Informatics, is now the tool of choice for computational structural biologists in the School of Pharmacy. The Jacobson Lab recently used ChimeraX to find a promising new cure for a drug-resistant...

Michael Keiser, PhD, and Kangway Chuang, PhD, want to use machine learning to speed the pace of drug discovery. By digging into the work of another lab, the pair realized how machine learning could lead scientists astray—and came up with methods to avoid its worst pitfalls.

Scientists in the UCSF School of Pharmacy recently identified the first drug-binding target site on a molecule known to play a role in Parkinson's disease, opening the door to a new generation of therapies for the condition.

School of Pharmacy researchers helped a free public database of potential drug molecules grow 100-fold.

Michael Keiser, PhD, received a Ben Barres Early Career Acceleration Award from the Chan Zuckerberg Initiative, which will fund his research into novel therapies for neurodegeneration.